EP0986375A2 - Utilisation de mkc-442 en combinaison avec d'autres agents antiviraux - Google Patents

Utilisation de mkc-442 en combinaison avec d'autres agents antiviraux

Info

Publication number
EP0986375A2
EP0986375A2 EP98914683A EP98914683A EP0986375A2 EP 0986375 A2 EP0986375 A2 EP 0986375A2 EP 98914683 A EP98914683 A EP 98914683A EP 98914683 A EP98914683 A EP 98914683A EP 0986375 A2 EP0986375 A2 EP 0986375A2
Authority
EP
European Patent Office
Prior art keywords
compound
mkc
pharmaceutically acceptable
hiv
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98914683A
Other languages
German (de)
English (en)
Inventor
Phillip A. Furman
Carey P. Moxham
David Barry
Katyna Dorroto-Esodo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Triangle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triangle Pharmaceuticals Inc filed Critical Triangle Pharmaceuticals Inc
Publication of EP0986375A2 publication Critical patent/EP0986375A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • HIV human immunodeficiency virus
  • BioChem Pharma, Inc. disclose racemic 2-substituted-4-substituted-l,3-dioxolanes that exhibit antiviral activity.
  • U.S. Patent No. 5,047,407 and European Patent Application No. 0 382 526, also assigned to BioChem Pharma, Inc. disclose that a number of racemic 2- substituted-5-substituted-l,3-oxathiolane nucleosides have antiviral activity, and specifically report that the racemic mixture of 2-hydroxymethyl-5-(cytosin- 1 -yl)- 1 ,3-oxathiolane (referred to below as BCH-189) has approximately the same activity against HIV as AZT, with little toxicity.
  • the (-)-enantiomer of the racemate BCH-189 known as 3TC, which is covered by U.S. Patent No. 5,539,116 to Liotta et al., is currently sold for the treatment of HIV in combination with AZT in humans in the U.S. It has also been disclosed that cis-2-hydroxymethyl-5-(5-fluorocytosin- 1 -yl)- 1,3- oxathiolane (“FTC”) has potent HIV activity.
  • MKC-442 is described, for example, in U.S. Patent No. 5,461,060.
  • MKC-442 although a nucleoside analogue, functions as a non-nucleoside reverse transcriptase inhibitor. It is considered an allosteric inhibitor because it appears to exert its activity by binding to an "allosteric position", i.e., one other than the binding site, of the enzyme.
  • Allosteric position i.e., one other than the binding site, of the enzyme.
  • MKC-442 may possess characteristics that address several of the therapeutic challenges of HIV. When tested in cell culture assay systems against wild-type (drug-sensitive) and several mutant strains of HIV known to be resistant to established non-nucleoside reverse transcriptase inhibitors, MKC-442 retained much of its ability to inhibit HIV replication.
  • MKC-442 displayed greater potency than nevirapine against wild-type and mutant strains of HIV.
  • Preclinical studies of MKC-442 in two drug combinations with AZT or with DDI and in three drug combinations with AZT and saquinavir have demonstrated synergistic inhibition of HIV replication.
  • the compound was generally well tolerated, with only a few participants experiencing minor adverse effects at the higher dose levels.
  • concentrations of the drug in the plasma reached levels mich higher than the levels required to suppress 90% of the virus in culture.
  • Preliminary data from a Phase I/II double-blind, placebo controlled trial designed to evaluate the safety and efficacy of repeated multiple oral doses of MKC-442 in HIV- infected patients has now also been evaluated.
  • the viral load was reduced by an average of 96% in all patients after one week. This reduction was mostly sustained at two weeks whereafter it was followed by a gradual increase in viral load from the nadir toward baseline levels.
  • a single point mutation at position 13 of the reverse transcriptase that may be associated with resistance was found in the virus obtained from some patients. In over 308 patient-weeks of drug exposure, MKC- 442 was well tolerated.
  • MKC-442 agents such as MKC-442 that are active against HIV induce mutations in the virus which reduce the efficacy of the drug.
  • MKC-442 exhibits a favorable pharmacokinetic and biodistribution profile, there is always a desire to improve these parameters.
  • MKC-442 exhibits a favorable pharmacokinetic and biodistribution profile, there is always a desire to improve these parameters.
  • MKC-442 exhibits a favorable pharmacokinetic and biodistribution profile, there is always a desire to improve these parameters.
  • MKC-442 exhibits a favorable pharmacokinetic and biodistribution profile, there is always a desire to improve these parameters.
  • MKC-442 exhibits a favorable pharmacokinetic and biodistribution profile, there is always a desire to improve these parameters.
  • metabolism of the drug which can lead to an increase in the plasma concentration of or exposure to MKC-442.
  • U.S. Patent No. 5,604,209 issued on February 18, 1997 to Ubasawa et al., and assigned to Mitsubishi Chemical Corporation, discloses that certain 6-benzyl-l- ethoxymethyl-5-substituted uracil derivatives, including MKC-442, and certain 2',3'- dideoxyribonucleosides, including 2',3'-dideoxyinosine (DDI), 3'-azido-3'-deoxythymidine (AZT), AZT triphosphate, and 2',3'-dideoxycytidine (DDC), exhibit a synergistic effect against HIV.
  • DKI 2',3'-dideoxyinosine
  • AZT 3'-azido-3'-deoxythymidine
  • DDC 2',3'-dideoxycytidine
  • Japanese Patent Application No. 9-18384 filed on January 31, 1997, by Mitsubishi Chemical Corporation discloses a method for the treatment of HIV that includes the administration of a 6-benzyl-l-ethoxymethyl-5 -substituted uracil derivative, including MKC- 442, in combination with two or more nucleoside-type reverse transcriptase inhibitors or their esters, and in particular, those selected from the group consisting of AZT, 2',3'-dideoxy-3'- thiacytidine (3TC), PMEA (9-(2-phosphonylmethoxyethyl) adenine (Gilead); PMPA: (R)-9- (2-phosphonyl-methoxypropyl)adenine); 1592U89 succinate ((lS,4R)-4-[2-amino-6- cyclopropyl-amino)-9H-purin-9-yl]-2-cyclopentene- 1 -methanol succinate); 2',3'- dideoxyinosine (
  • MKC-442 In light of the strong activity of MKC-442 against HIV, it is an object of the present invention to provide a method and composition that includes MKC-442 for the treatment of patients infected with HIV that exhibits advantageous or improved pharmacokinetic, biodistribution, metabolic, resistance or other parameters over administration of MKC-442 alone.
  • MKC-442 can be administered in combination with one or more antiviral agents to achieve an advantageous therapeutic effect against HIV. In some cases, the enhanced therapeutic effect is not attainable by administration of either agent alone. In a preferred but not necessary embodiment, the effect of administration of the two agents in combination or alternation is synergistic. In one preferred embodiment, MKC-442 is administered in combination with a protease inhibitor.
  • MKC-442 is administered in combination or alternation with indinavir (Crixivan), nelf ⁇ navir ([3S-[2(2S*,3S*),3-alpha,4-a-beta,8a-beta-]]- N-(l,l-dimethylethyl)decahydro-2-)2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4- (phenylthio)butyl]-3-isoquinolincarboxamide mono-methanesulfonate) (Viracept), saquinavir (Invirase), or 141 W94 (amprenavir; (S)-tetrahydrofuran-3-yl-N-[(lS,2R)-3- [N-[(4-aminophenyl)sulfonyl] -N-isobutylamino]- 1 -benzyl-2-hydroxypropyl]c
  • MKC-442 is administered in combination or alternation with a nucleoside analog, including FTC, 3TC, or abacavir (1592U89) which is (1 S,4R)-4-[2-amino-6-cyclopropyl-amino)-9H-purin-9-yl]-2-cyclopentene- 1 -methanol succinate.
  • a nucleoside analog including FTC, 3TC, or abacavir (1592U89) which is (1 S,4R)-4-[2-amino-6-cyclopropyl-amino)-9H-purin-9-yl]-2-cyclopentene- 1 -methanol succinate.
  • MKC-442 is administered in combination with a nonnucleoside reverse transcriptase inhibitor such as DMP-266 (efarirenz; 1 ,4-dihydro-2H- 3,l-benzoxazin-2-one); delavirdine, (l-[3-(l-methyl-ethyl)amino]-2-pyridinyl-4- [[5-[(methylsulfonyl)amino]- lH-indol-2-yl]carbonyl]-, monoethanesulfonate); or nelfinavir
  • DMP-266 efarirenz; 1 ,4-dihydro-2H- 3,l-benzoxazin-2-one
  • delavirdine (l-[3-(l-methyl-ethyl)amino]-2-pyridinyl-4- [[5-[(methylsulfonyl)amino]- lH-indol-2-yl]carbony
  • an effective dosage of each agent is administered serially, whereas in combination therapy, an effective dosage of two or more agents are administered together.
  • the dosages will depend on such factors as absorption, biodistribution, metabolism and excretion rates for each drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
  • Suitable dosage ranges for protease inhibitors for example, nelfinavir and indinavir
  • suitable dosage ranges for other compounds described herein are also found ini public literature or can be identified using known procedures. These dosage ranges can be modified as desired to achieve a desired result.
  • the disclosed combination and alternation regiments are useful in the prevention and treatment of HIV infections and other related conditions such as AIDS-related complex (ARC), persistent generalized lymphadenopathy (PGL), AIDS-related neurological conditions, anti-HIV antibody positive and HIV-positive conditions, Kaposi's sarcoma, thrombocytopenia purpurea and opportunistic infections.
  • these compounds or formulations can be used prophylactically to prevent or retard the progression of clinical illness in individuals who are anti-HIV antibody or HIV-antigen positive or who have been exposed to HIV.
  • Figure 1 is an isobologram analysis of the combination of MKC-442 and indinavir in cell culture.
  • Figure 2 is an isobologram analysis of the combination of MKC-442 and nelfinavir in cell culture.
  • MKC-442 can be administered in combination with one or more antiviral agents to achieve an advantageous therapeutic effect to inhibit HIV replication. In most cases, the enhanced therapeutic effect is not attainable by administration of either agent alone. In a preferred but not necessary embodiment, the effect of administration of the two agents in combination or alternation is synergistic.
  • X is oxygen or sulfur
  • R 1 is ethyl or isopropyl
  • R 2 and R 3 are independently hydrogen
  • C r C 4 alkyl or halogen chlorine, bromine, iodine, or fluorine
  • the compound is MKC-442.
  • Any of the compounds described herein for combination or alternation therapy can be administered as any derivative that upon administration to the recipient, is capable of providing directly or indirectly, the parent compound, or that exhibits activity itself.
  • Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as “physiologically acceptable salts”), and a compound which has been alkylated or acylated at an appropriate position.
  • physiologically acceptable salts alternatively referred to as "physiologically acceptable salts”
  • the modifications can affect the biological activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivative and testing its antiviral activity according to known methods.
  • salts refers to salts that retain the desired biological activity of the herein-identified compounds and exhibit minimal undesired toxicological effects.
  • Non-limiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as amino acid, acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a
  • Drug resistance most typically occurs by mutation of a gene that encodes for an enzyme used in the viral life cycle, and most typically in the case of HIV, in either the reverse transcriptase or protease genes. It has been demonstrated that the efficacy of a drug against HIV infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation(s) from that selected for by the principle drug. Alternatively, the pharmacokinetics, biodistribution, or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.
  • the second antiviral agent for the treatment of HIV in one embodiment, can be a protease inhibitor, or a reverse transcriptase inhibitor (a "RTI"), which can be either a synthetic nucleoside (a "NRTI”) or a non-nucleoside compound (a "NNRTI”).
  • RTI reverse transcriptase inhibitor
  • the second (or third) compound can be a pyrophosphate analog, or a fusion binding inhibitor.
  • MKC-442 is administered in combination or alternation with FTC (2',3'-dideoxy-3'-thia-5-fluorocytidine); 141W94 (amprenavir, Glaxo Wellcome, Inc.); Viramune (nevirapine), Rescriptor (delavirdine); or DMP-266 (efavirenz).
  • MKC-442 is administered in combination or alternation with abacavir (1592U89), which is ( 1 S,4R)-4-[2-amino-6-cyclopropyl-amino)-9H- purin-9-yl]-2-cyclopentene- 1 -methanol succinate.
  • antiviral agents that can be used in combination or alternation with the compounds disclosed herein for HIV therapy include 3TC; foscarnet; carbovir, acyclovir, interferon, stavudine, CS-92 (3'-azido-2',3'-dideoxy-5-methyl-cytidine), and b-D- dioxolane nucleosides such as b-D-dioxolanylguanine (DXG), b-D-dioxolanyl-2,6- diaminopurine (DAPD), and b-D-dioxolanyl-6-chloropurine (ACP).
  • DXG b-D-dioxolanylguanine
  • DAPD b-D-dioxolanyl-2,6- diaminopurine
  • ACP b-D-dioxolanyl-6-chloropurine
  • Preferred protease inhibitors include indinavir ( ⁇ l(l,S,2R),5(S)]-2,3,5-trideoxy-N- (2,3-dihydro-2-hydroxy-lH-inden-l-yl)-5-[2-[[(l,l-dimethylethyl)amino]carbonyl]-4-(3- pyridinylmethyl)- 1 -piperazinyl]-2-(phenylmethyl)-D-erythro-pentoamide sulfate; Merck), nelfinavir (Agouron), ritonavir (Abbot), saquinavir (Roche) and DMP-450 ⁇ [4R-4(r-a,5-a , 6- b,7-6)]-hexahydro-5,6-bis(hydroxy)-l,3-bis(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)- 2H-l,3-d
  • Nonlimiting examples of other compounds that can be administered in combination or alternation with MKC-442 to augment the properties of the drug on administration include abacavir: (lS,4R)-4-[2-amino-6-cyclopropyl-amino)-9H-purin-9-yl]-2- cyclopentene-1-methanol succinate (1592U89, a carbovir analog; Glaxo Wellcome); AzddU:3'-azido-2',3'-dideoxyuridine; zidovudine: AZT, 3'-azido-3'-deoxythymidine (Glaxo Wellcome); BILA 1906: N- ⁇ lS-[[[3-[2S- ⁇ (l,l-dimethylethyl)amino]carbonyl ⁇ -4R-]3- pyridinylmethyl)thio]- 1 -piperidinyl]-2R-hydroxy- 1 S-(phenylmethyl)propyl]amino]
  • HBY097 S-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3,4- dihydroquinoxalin-2(lH)-thione;
  • HEPT l-[(2-hydroxyethoxy)methyl]6- (phenylthio)thymine;
  • KNI-272 (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid-containing tripeptide;
  • L- 735,524 hydroxy-aminopentane amide HIV-1 protease inhibitor (Merck);
  • L-697,661 3- ⁇ [(-
  • L- FDDC (-)-b-L-5-fluoro-2',3'-dideoxycytidine
  • L-FDOC (-)-b-L-5-fluoro-dioxolane cytosine; 6-benzyl-l-ethoxymethyl-5-isopropyluracil (I-EBU; Triangle/Mitsubishi); nevirapine: 11- cyclopropyl-5,l l-dihydro-4-methyl-6H-dipyridol[3,2-b:2',3'-e]diazepin-6-one (Boehringer- Ingelheim); PFA: phosphonoformate (foscarnet; Astra); PMEA: 9-(2- phosphonylmethoxyethyl) adenine (G)
  • MKC-442 is administered in combination with a protease inhibitor (LG 1350) of the structure:
  • acyl refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen, C, to C 4 alkyl or C, to C 4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzy
  • nucleosides described herein or other compounds that contain a hydroxyl or amine function can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside.
  • a number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the hydroxyl group of the compound or of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide.
  • substituent groups that can replace one or more hydrogens on the phosphate moiety or hydroxyl are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, Antiviral Research, 27
  • the active nucleoside or other hydroxyl containing compound can also be provided as an ether lipid (and particularly a 5 '-ether lipid for a nucleoiside), as disclosed in the following references, which are inco ⁇ orated by reference herein: Kucera, L.S., N. Iyer, E.
  • Nonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently inco ⁇ orated into the nucleoside or other hydroxyl or amine containing compound, preferably at the 5 '-OH position of the nucleoside or lipophilic preparations include U.S. Patent Nos. 5,149,794 (Sep. 22, 1992, Yatvin et al.); 5,194,654 (Mar. 16, 1993, Hostetler et al., 5,223,263 (June 29, 1993, Hostetler et al.); 5,256,641 (Oct.
  • Alkyl hydrogen phosphate derivatives of the anti-HIV agent AZT may be less toxic than the parent nucleoside analogue.
  • S-acyl-2-thioethyl group also referred to as "SATE".
  • the inhibitory effects of combined antiviral agents were evaluated using the human T cell line, MT2. Infection of this cell line with HIV results in cell death. Inhibition of the HIV induced cytopathic effect by the combined agents is measured in a MTT (3 -[4, 5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) based assay.
  • MTT 3-[4, 5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
  • the mitochondrial dehydrogenases of viable cells will cleave the tetrazolium ring of MTT, yielding pu ⁇ le formazan crystals which are soluble in acidified isopropanol. The resulting pu ⁇ le solution is measured spectrophotometrically. The amount of pu ⁇ le dye formed is directly related to the number of viable cells.
  • CPE viral cytopathic effects
  • the assays are performed in a 96 well microtiter plate. Each compound to be tested is made up at 4 times the final concentration to allow for dilution by cells and other test compounds.
  • Compounds are prepared in complete RPMI media (RPMI 1640 plus 10% fetal bovine semm plus 20 mg/mL gentamicin). Two drugs are tested simultaneously on each plate using a checkerboard design. Serial dilutions of the first dmg are added to the vertical wells (50 mL/well) of the plate (columns 2 - 11). Serial dilutions of the second dmg (50 mL/well) are then added to the plate across horizontal rows (rows A - G).
  • Column #2 and row H contain dilutions of only one compound. EC 50 values obtained from these wells are a measure of the antiviral activity of each compound alone. Column #1 contains vims control, infected cells grown in the absence of compound, and Column 12 contains cell control, mock infected cells.
  • MT2 cells are infected with the LAI strain of HIV at a multiplicity of infection of 0.01 in complete RPMI containing 2 mg/mL polybrene for 2 hours at 37°C. Following infection, cells diluted to 2.5 x 10 5 cells/mL in complete RPMI media. 100 mL of the cell suspension are seeded onto 96 well plates, 2.5 x 10 4 cells/well, containing test compounds as described above. The final volume in each well is 200 mL. Plates are sealed and incubated at 37°C in a humidified 5% CO 2 incubator for 5 days.
  • a dose response curve for each individual compound is generated using the abso ⁇ tion values of the cell controls as 100% protection and no dmg vims infected cells as 0% protection. From this dose response curve a EC 50 value is calculated and is defined as the concentration of dmg that inhibits 50% of viral induced CPE. The effects of the combined compounds were obtained using the isobologram technique (Elion, G.B. et al, 1954, J. Biol.
  • MKC-442 is advantageously delivered in combination or alternation with another antiviral agent that exhibits a different mutation profile than MKC-442.
  • Humans suffering from effects caused by any of the diseases described herein, and in particular, HIV infection can be treated by administering to the patient an effective amount of MKC-442 in combination with one or more agents described above or a pharmaceutically acceptable derivative or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent.
  • the active materials can be administered by any appropriate route, for example, orally, parenterally, enterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
  • the active compounds are included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a fherapeutically effective amount of compound to inhibit viral replication in vivo, especially HIV replication, without causing serious toxic effects in the treated patient.
  • inhibitory amount is meant an amount of active ingredient sufficient to exert an inhibitory effect as measured by, for example, an assay such as the ones described herein.
  • a preferred dose of the compound for all the above-mentioned conditions will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day.
  • the effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent nucleoside to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.
  • the compounds are conveniently administered in unit any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form.
  • An oral dosage of 50 to 1000 mg is usually convenient.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 mM, preferably about 1.0 to 10 mM. This may be achieved, for example, by the intravenous injection of a 0.1 to % solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
  • concentration of active compound in the dmg composition will depend on abso ⁇ tion, distribution, metabolism and excretion rates of the dmg as well as other factors known to those of skill in the art.
  • dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • a preferred mode of administration of the active compound is oral.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be inco ⁇ orated with excipients and used in the form of tablets, troches, or capsules.
  • Pharmaceutically compatible bind agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or com starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or com starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
  • the compounds can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the compounds or their pharmaceutically acceptable derivative or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, protease inhibitors, or other nucleoside or non-nucleoside antiviral agents, as discussed in more detail above.
  • Solutions or suspensions used for parental, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Co ⁇ oration.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers, these may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No.
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
  • An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container.
  • the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention se rapporte à l'utilisation de MKC-442 en combinaison ou en alternance avec d'autres agents antiviraux, pour le traitement de patients infectés par le VIH.
EP98914683A 1997-04-07 1998-04-07 Utilisation de mkc-442 en combinaison avec d'autres agents antiviraux Withdrawn EP0986375A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4190997P 1997-04-07 1997-04-07
US41909P 1997-04-07
PCT/US1998/007248 WO1998044913A2 (fr) 1997-04-07 1998-04-07 Utilisation de mkc-442 en combinaison avec d'autres agents antiviraux

Publications (1)

Publication Number Publication Date
EP0986375A2 true EP0986375A2 (fr) 2000-03-22

Family

ID=21919000

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98914683A Withdrawn EP0986375A2 (fr) 1997-04-07 1998-04-07 Utilisation de mkc-442 en combinaison avec d'autres agents antiviraux

Country Status (6)

Country Link
US (2) US6410546B1 (fr)
EP (1) EP0986375A2 (fr)
JP (1) JP2001518899A (fr)
AU (1) AU6898498A (fr)
CA (1) CA2285577A1 (fr)
WO (1) WO1998044913A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
WO2004054586A1 (fr) * 2002-12-16 2004-07-01 Boehringer Ingelheim International Gmbh Utilisation d'une combinaison contenant un inhibiteur non nucleosidique de la transcriptase inverse (innti) avec un inhibiteur de cytochrome p450, tel qu'un inhibiteur de la protease
EP1610782A1 (fr) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Combinaison antivirale d'une dipyridodiazepinone et compose antiretroviral

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5587777A (en) 1978-12-27 1980-07-02 Ono Pharmaceut Co Ltd Pyrimidine derivative, its preparation and antitumorigenic agent
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
ES2196004T3 (es) 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
KR0155168B1 (ko) 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
EP0631783A1 (fr) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Combinaisons antivirales de 2',3'-didéoxy-ribonucléosides avec des dérivés 5-substitués du 6-benzyl-1-éthoxyméthyl-uracile
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9844913A2 *

Also Published As

Publication number Publication date
CA2285577A1 (fr) 1998-10-15
US6410546B1 (en) 2002-06-25
WO1998044913A3 (fr) 1999-01-28
US20020002166A1 (en) 2002-01-03
WO1998044913A2 (fr) 1998-10-15
AU6898498A (en) 1998-10-30
JP2001518899A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
US7468357B2 (en) Nucleosides with anti-hepatitis B virus activity
US6407077B1 (en) β-L nucleosides for the treatment of HIV infection
WO2007097991A2 (fr) Méthodes et trousses pour administrer des agents antiviraux
US6197777B1 (en) Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
US6410546B1 (en) Use of MKC-442 in combination with other antiviral agents
US20050113321A1 (en) DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor
US20110053884A1 (en) Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase
JP2011251968A (ja) ＨＩＶ感染の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
AU2003261475B2 (en) Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection
AU2006246473B2 (en) Nucleosides with anti-hepatitus B virus activity
AU2002258368A1 (en) DAPD combination therapy with IMDPH inhibitors such as ribavirin or mycophenolic acid
WO2004009595A1 (fr) Polytherapie avec des inhibiteurs de desydrogenase de monophosphate inosine et 1,3-dioxolanes
MXPA99009253A (es) Actividades anti-virus de inmunodeficiencia humana y anti-virus de hepatitis b de la sintesis de nucleosidos de 1,3-oxaselenolano

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991105

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991105;LT PAYMENT 19991105;LV PAYMENT 19991105;MK PAYMENT 19991105;RO PAYMENT 19991105;SI PAYMENT 19991105

17Q First examination report despatched

Effective date: 20000512

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 37/00 B

Ipc: 7A 61K 31/00 A

RTI1 Title (correction)

Free format text: USE OF MKC-442 IN COMBINATION WITH NUCLEOSIDE ANALOGS

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 37/00 B

Ipc: 7A 61K 31/00 A

RTI1 Title (correction)

Free format text: USE OF MKC-442 IN COMBINATION WITH NUCLEOSIDE ANALOGS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021030